Alphamab Oncology announced that it has repurchased 1,681,000 shares under its Share Repurchase Mandate. The company stated that the repurchases are intended to reflect confidence in its business outlook and create value for shareholders. The share repurchases are being financed by existing available cash and will be conducted in compliance with all applicable laws and regulations. The company has not specified the timing, quantity, or price of future repurchases.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief on November 07, 2025, and is solely responsible for the information contained therein.